The approval allows Cephalon to market Effentora in the 27 member states of the EU, as well as Iceland and Norway.
Alain Aragues, president of Cephalon Europe, said: “Cephalon continues to build its presence in Europe, the Middle East and Africa and activities are ongoing to make Effentora available quickly in the EU member countries.”